161 related articles for article (PubMed ID: 28585003)
1. Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.
Pan L; Duan J; Qiao W; Bi L; Wu D; Fan Z; Yang M
Breast Cancer; 2017 Nov; 24(6):790-793. PubMed ID: 28585003
[TBL] [Abstract][Full Text] [Related]
2. Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
Kaygusuz-Atagunduz I; Toptas T; Yumuk F; Firatli-Tuglular T; Bayik M
J Cancer Res Ther; 2014; 10(4):1107-8. PubMed ID: 25579564
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
4. Low-grade ductal carcinoma in situ (DCIS) arising in a fibroadenoma of the breast during 5 years follow-up: A case report.
Shojaku H; Hori R; Yoshida T; Matsui K; Shimada K; Takayanagi N; Noguchi K
Medicine (Baltimore); 2021 Mar; 100(10):e24023. PubMed ID: 33725814
[TBL] [Abstract][Full Text] [Related]
5. Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Elm'hadi C; Khmamouche MR; Tanz R; Toreis M; Mahtat E; Allaoui M; Oukabli M; Messaoudi N; Errihani H; Ichou M
J Med Case Rep; 2017 Jan; 11(1):10. PubMed ID: 28069070
[TBL] [Abstract][Full Text] [Related]
6. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
[TBL] [Abstract][Full Text] [Related]
7. [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Müller MC; Lahaye T; Hochhaus A
Dtsch Med Wochenschr; 2002 Oct; 127(42):2205-7. PubMed ID: 12397549
[TBL] [Abstract][Full Text] [Related]
8. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
11. [A practice guideline for diagnosis and treatment of ductal in situ carcinoma of the breast].
Delaloye JF; Wight E; Fink D; Otto R; Steiner R;
Gynakol Geburtshilfliche Rundsch; 2006; 46(1-2):64-7. PubMed ID: 16452823
[No Abstract] [Full Text] [Related]
12. [Imatinib therapy in chronic myeloid leukemia].
Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
[TBL] [Abstract][Full Text] [Related]
13. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Breccia M; Martelli M; Cannella L; Russo E; Finolezzi E; Stefanizzi C; Levi A; Frustaci A; Alimena G
Leuk Res; 2008 Feb; 32(2):353-5. PubMed ID: 17825907
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
[TBL] [Abstract][Full Text] [Related]
15. Integrative tumor board: recurrent breast cancer or new primary? Case Presentation.
Schmaltz J
Integr Cancer Ther; 2003 Sep; 2(3):268-70. PubMed ID: 15035889
[No Abstract] [Full Text] [Related]
16. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.
Yadav U; Solanki SL; Yadav R
J Cancer Res Ther; 2013; 9(3):484-6. PubMed ID: 24125987
[TBL] [Abstract][Full Text] [Related]
17. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
18. An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
Paquin D; Sacco D; Shamshoian J
Math Biosci; 2015 Apr; 262():117-24. PubMed ID: 25659886
[TBL] [Abstract][Full Text] [Related]
19. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
20. Annual report of the Japanese Breast Cancer Registry for 2017.
Hayashi N; Kumamaru H; Isozumi U; Aogi K; Asaga S; Iijima K; Kadoya T; Kojima Y; Kubo M; Miyashita M; Miyata H; Nagahashi M; Niikura N; Ogo E; Tamura K; Tanakura K; Yamamoto Y; Yoshida M; Imoto S; Jinno H
Breast Cancer; 2020 Sep; 27(5):803-809. PubMed ID: 32710374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
